MedCap acquires and develops profitable, market-leading niche companies in the life science industry in Northern Europe that have the potential to grow internationally. The group conducts operations in two areas: MedTech and Specialty Pharma.
During the fiscal year 1 January – 31 December 2020, the MedCap group exhibited annual sales of approximately SEK 817.4 million and EBITDA of SEK 157.2 million, and had approximately 350 employees. The group is listed on the Mid Cap list of Nasdaq Stockholm.